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Abstract
Over the last 20 years, haematopoietic stem cell transplantation (HSCT) has been used to treat patients with severe
autoimmune and inflammatory diseases whose response to standard treatment options has been limited, resulting in a poor
long-term prognosis in terms of survival or disability. The vast majority of patients have received autologous HSCT where
an increasing evidence-base supports its use in a wide range of autoimmune diseases, particularly relapsing remitting MS,
systemic sclerosis and Crohn’s disease. Compared with standard treatments for autoimmune diseases, HSCT is associated
with greater short-term risks, including a risk of treatment-related mortality and long-term complications. There is a need for
a careful appraisal of potential benefits and risks by disease and transplant specialists working closely together with patients
and carers to determine individual suitability for HSCT. HSCT should be conducted in accredited transplant centres with
robust arrangements for long-term follow-up with both disease and transplant specialists. The aim of this open-access
position statement is to provide plainly worded guidance for patients and non-specialist clinicians considering HSCT for an
autoimmune disease, especially when treatment abroad is being considered. Recent technical publications in the field have
been referenced to support the statement and provide more detail for clinicians advising patients.
Introduction
Autoimmune diseases (ADs) are a broad group of illnesses
where the body’s immune system reacts against its own
tissues and organs. The immune attack is followed by
chronic inflammation and abnormal healing, which may be
associated with permanent organ damage, disability and
poor quality of life. In some cases, severe ADs may shorten
life expectancy or even be immediately life-threatening.
The types of organs affected vary between ADs. For
example, systemic sclerosis, lupus, vasculitis and other
connective tissue diseases affect many organs, typically
causing inflammation and scarring of the skin, heart,
lungs, kidneys and other organs. Multiple sclerosis (MS)
affects the brain and spinal cord, whereas Crohn’s disease
affects the gut.
Treatment with immunosuppressant drugs, including
disease modifying treatments (DMTs), may be successful in
controlling the AD, but there is an increased susceptibility
to infection and organ damage, which add to the problems
of living with an AD.
Some patients have very aggressive forms of auto-
immune disease which are poorly controlled by standard
therapies. In some of these severely affected patients, there
may be benefit in considering bone marrow transplantation
(BMT), or, as it is now more commonly known, haemato-
poietic stem cell transplantation (HSCT) [1–3].
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HSCT is commonly used for the treatment of serious blood
diseases, including leukaemia, myeloma and lymphomas.
Many haematology departments will provide HSCT as a
treatment for these common indications, having carefully
weighed up the survival benefits and serious risks of HSCT
against the non-transplant treatment options, such as che-
motherapy and modern biological agents [4, 5].
The process of HSCT involves giving high doses of
chemotherapy and/or radiotherapy and then infusing
mobilized blood, cord blood or marrow-derived (i.e.,’ hae-
matopoietic’) stem cells from the patients themselves
(autologous or auto-transplant) or from donors (allogeneic
or allo-transplant) to rebuild the bone marrow and the
immune system, hopefully without the disease.
The HSCT process is summarised in Fig. 1. Recognised
early complications include acute toxicities experienced
during the procedure, such as infection, bleeding, anaemia
and organ toxicities. Blood transfusions are usually needed
to support the patients during this phase of the treatment.
Complications may be life-threatening and irreversible and
therefore HSCT should only be performed after a full dis-
cussion of the risks and how they may be justified in terms
of potential benefits from the treatment. Treatment-related
mortality (TRM) risks depend on the type of transplant, the
disease being treated and the individual patient. Even in
patients treated in accredited transplant centres, TRM risk
ranges from around 1% in good risk patients undergoing
autologous HSCT to considerably higher in patients with
more risk factors (e.g., severe organ damage or disability)
and with allogeneic HSCT, where TRM risk commonly
exceeds 10%. Responsible treating clinicians need to openly
discuss and individualise these risks for patients as part of
the informed consent process.
The risks of the HSCT procedure are not limited to the
inpatient phase prior to recovery of blood counts [6–8].
Following hospital discharge after the HSCT procedure,
given the risk of ongoing complications, especially the risk
of sudden onset of serious and life-threatening complica-
tions including infection, there should always be robust
plans for follow up and urgent management of complica-
tions. Patients should be able to self-refer into a haematol-
ogy or other department familiar with HSCT on a 7-day,
24-h basis, and the transplant unit should organise regular
outpatient monitoring in the first 2 years following the
procedure and thereafter if needed. The risks of infection
persist for long periods after HSCT, and ‘prophylactic’
(preventative) antibiotics are recommended for many
months, or sometimes even life-long. Even though patients
may feel well, some complications, including certain types
of pneumonia, may be rapid in their onset and progression
and much more challenging to treat when established.
Patients need to be monitored, and provided with a con-
sistent supply of prophylactic (preventative) antibiotics,
which reduce hospitalisation for serious and sometimes
life-threatening complications. Vaccination should be con-
sidered according to current guidelines for immunocom-
promised patients [9].
Long-term monitoring is essential. The so-called ‘late
effects’ of HSCT are common and may involve many
organ systems, including glandular (endocrine), bone,
cardiovascular, respiratory and neurological. HSCT can
also result in an increased risk of ‘new’ cancers, and have
an impact on patients’ psychological and emotional well-
being. Reproductive impairment can be frequent, and
programmes for prevention of chemotherapy-associated
sterility should therefore be proposed prior to HSCT.
Allogeneic HSCT may also be associated with risks of
graft-versus-host disease, a potentially severe immune
complication that may affect several organs. There is even
a risk of new ADs (known as ‘secondary’ autoimmune
diseases) after both autologous and allogeneic HSCT. In
recognition of these ‘late effects’, the EBMT and other
organisations have produced recommendations for long-
term follow-up of patients who should have life-long
follow-up by clinicians familiar with ‘late effects’ fol-
lowing HSCT, irrespective of where the procedure has
been performed [6–9].
Transplant centres should have approval of their ‘quality’
by external accreditation organisations (Joint Accreditation
Committee of ISCT & EBMT, JACIE, or its North Amer-
ican equivalent, the Foundation for Cellular Therapy,
FACT), and there is published evidence supporting
improved safety and survival outcomes with accreditation
[10, 11].
2. Stem cells collected
from peripheral blood
1. Mobilise stem cells
using growth factor and
chemotherapy
7. Further follow-up as
outpatient for 2-3 months
with regular blood tests
and medication
6. Support with blood
products and antibiotics
(approximately 2 weeks)
5. Stem cells thawed
and re-infused






Fig. 1 Summary of autologous HSCT procedure. In addition, robust
long-term follow-up arrangements should be individualised with each
patient with both disease and transplant specialists
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Haematopoietic stem cell transplantation
(HSCT) for ADs
Over the last 20 years, HSCT has also been used to treat
severe ADs, as it is an effective means by which to suppress
the abnormal inflammation and associated scarring [1–3]. It
is also possible that HSCT can rebuild an altered immune
system that does not regenerate the original AD, or at least
leads to a milder form and better disease control. To date,
several thousand patients with ADs have been treated
worldwide with HSCT, with almost 3000 patients registered
in the EBMT registry (summarised in Table 1).
The main ADs treated are currently relapsing remitting
MS, systemic sclerosis (SSc), systemic lupus erythematosus
(SLE or ‘lupus’) and Crohn’s disease. Other rare immune
disorders have been treated in smaller numbers. The vast
majority of patients have been treated with autologous
HSCT, with MS, SSc and Crohn’s disease being the main
current indications, reflected by the registrations for the
years following the publication of the EBMT ADWP
guidelines and recommendations [12] in 2012 (Table 1). A
small proportion of patients have received allogeneic
HSCT, predominantly for rare diseases in the paedatric
age group.
It should be emphasized that HSCT is not a form of
‘regenerative’ stem cell therapy in the same way as many
scientists hope that stem cells may be used to rebuild new
organs. HSCT may lead to ‘re-setting‘ or ‘re-booting’ of the
immune system, which in turn may lead to improvement in
damaged organs and tissues. HSCT works best if active
inflammation can be switched off, but the effect of HSCT may
be limited (or nothing at all) if there is no active inflammation.
There is no proof that the blood stem cells can directly rebuild
specialised tissues, although in the absence of inflammation
some damaged tissues and organs may heal over time. The
potential mechanism by which autologous HSCT leads to a re-
setting or re-balancing of the immune system in autoimmune
disease is summarised in Fig. 2.
Although HSCT is common in many haematology and
oncology departments, use of HSCT in ADs is relatively
rare and only a small number of transplant centres in each
country have a good level of experience in working with
disease specialists to select the most appropriate patients
with AD and then deliver the HSCT treatment as safely as
possible.
The type of HSCT almost always used in patients with
severe ADs is autologous HSCT (or ‘auto-transplant’).
Auto-transplant is more safely delivered compared with
allogeneic HSCT (or ‘allo-transplant’), which is a much
more complex procedure requiring a donor. Even so, there
are significant risks and toxicities with autologous HSCT,
which are an important consideration, especially if the AD
has already caused significant organ damage and disability.
In view of these toxicities and risks, it is very important that
patients have a full discussion with their transplant and
autoimmune disease specialist teams.
The individual patient’s response to HSCT is dependent on
the specific AD and the stage of the disease at the time of
treatment e.g., whether the inflammatory disease process can
be ‘switched off’ before it has become irreversible or has
caused permanent organ damage. Some patients have had
very profound responses lasting many years, far more than
expected from treatment with standard therapies, but others
respond less well or experience a relapse of their AD soon
after the transplant. The benefit of HSCT in some ADs (MS,
SSc and Crohn’s disease) has been shown in randomized
controlled trials (RCTs) against the best available conventional
therapy for an AD. However, there is always need for more
evidence to help improve outcomes, and, when possible, AD
patients should be treated on ethically approved clinical
studies.
Specific advice to patients considering HSCT
for their AD
We recommend that before starting treatment, patients
should inform themselves firstly about current disease and
treatment guidelines, secondly about the professional com-
petence of the clinicians and thirdly the experience and
accreditation status of the transplant centre.
The European Society of Blood & Marrow Transplan-
tation (EBMT) has published a number of guidelines and
recommendations for the use of HSCT in ADs [11–13].
Other organisations and individual health professionals
have also made recommendations in specific diseases
[14–17]. Whereas these guidelines are primarily intended
for a professional readership and therefore written in a
technical language, they are openly accessible to all.
Timing of HSCT is central to decision-making. The
severity of the autoimmune disease, its treatment-resistance
and availability of other treatment options are essential con-
siderations. However, HSCT needs to be considered before
organ damage caused by the autoimmune disease becomes
irreversible (limiting benefits) and before the risks of HSCT
are significantly increased by compromised vital organ
function. Balancing potential benefits and risks for individual
patients is often complex and requires disease specialists and
transplant clinicians to work closely together.
The EBMT recommend that patients ask their transplant
and disease specialists to explain any aspect of the guide-
lines, including whether treatment is in line with the pub-
lished recommendations.
Treating clinicians should be active in the EBMT and/or
other national and international professional societies,
which means that they should follow published guidelines,
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report their outcomes to the EBMT (or equivalent profes-
sional society) and maintain their professional competencies
in this highly specialized field. EBMT membership infor-
mation is available from www.EBMT.org and accreditation
status on www.JACIE.org websites.
Importantly, patients should ask about short- and long-
term side-effects of the treatment and the level of risk of
death from the treatment and the severe AD to make a
balanced decision. Patients should ask their transplant and
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Fig. 2 Mechanism of immune
re-setting with autologous
HSCT in autoimmune diseases
Table 1 Summary of major
categories and types of
autoimmune diseases treated
with HSCT in the EBMT
registry, as per August 2018





Total children (≤18 years
at the time of transplant,
1994–2018)
Total patients treated
in the last 6 years (all
ages, 2012–2017)
All diseases 2387 162 1090
Neurological diseases
Multiple sclerosis 1232 27 679
Other neurological diseases 94 3 51
Rheumatological diseases












Crohn’s and other 177 15 83
Haematological autoimmune









The table summarises activity in autologous HSCT, which accounts for the vast majority of procedures.
Since 1996, 145 allogeneic transplants (from related and unrelated donors) have been performed for
autoimmune diseases, approximately three quarters (73%) in children under the age of 18 for a range of
haematological, rheumatological and other conditions
Bold type denotes the sum total for each column
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unit in general, whether the transplant unit is accredited (by
JACIE, FACT or equivalent) and their specific experience
of treating your particular AD with HSCT. Ideally, the
transplant centres should have accreditation and have a
good track record of experience and academic publication in
the disease for which HSCT is being considered.
Patients may also want to ask for an independent spe-
cialist opinion or whether their case has had a documented
discussion with a wider group of professionals within a
multidisciplinary team setting (i.e., an MDT meeting).
Ideally patients should be seen and followed up in a com-
bined clinic involving both disease and transplant specia-
lists. Updates on specific ADs are provided on the EBMT
websites listed at the end of this position statement.
One exception for being treated outside established
guidelines is treatment on a clinical trial approved by a
research ethics committee (REC) or institutional review
board (IRB), which may, for example, be testing whether a
new technique might provide an advantage over existing
treatments. In this instance, patients will be counselled and
asked to provide an informed consent for the trial.
Even if patients are not on a clinical trial, full informed
consent for treatment and also for data reporting is an EBMT
requirement for good clinical practice and data protection. In
order for the transplant community to gain a better under-
standing of the long-term side-effects of this treatment, it is
important that transplant centres report data relating to
transplant treatments to the EBMT or an equivalent registry.
In the EBMT, patient data will be handled in an anonymous
(and/or pseudonymised) fashion and in line with current
general data protection regulation (GDPR).
Figure 3a–d summarises recent activity and JACIE
accreditation status in EBMT reporting centres for autologous
HSCT procedures in ADs, both overall and for specific dis-
ease categories. The information is primarily intended as a
resource for clinicians in transplant centres and disease spe-
cialists who wish to make contact with experienced EBMT
centres for advice, support, referral or other partnership
arrangements aimed at optimising patient care whilst
accommodating geographical considerations. The information
may also be useful to patients and other carers; however,
independent self-referral is strongly discouraged.
Treatment abroad
Patients should do their best to enquire whether treatment is
available within their own health service, and, if not, they
should question why. It may be that treatment is available
under specific circumstances that do not cover specific types
of AD or a disease specialist may not consider it a best
option. If treatment is planned outside of their home country
patients should think carefully about their decision, as it
may not only have financial implications, but there may be
exposure to unnecessary risks to their health and well-being.
If treatment is unavailable in a patient’s home country, it is
more satisfactory if they travel and receive treatment with
the full support of a disease specialist and transplant spe-
cialist who knows them well and is familiar with the
centre providing the treatment, or at least their general
practitioner. This may enable direct communication with
transplant and disease specialist teams undertaking the
transplant. Independent self-referral by patients is strongly
discouraged.
Even if the initial phase of the transplant is a success,
patients should be aware that risks of treatment, such as
infection and organ damage, last for many months and, in
some cases, years after the transplant procedure. As with
HSCT in other settings, ongoing follow-up and support is
recommended, along with the need for rapid self-referral to a
locally available transplant or other specialist haematology
unit in case of infections or other emergencies. The follow-up
should include the provision of monitoring for ‘late effects’ of
HSCT. These aspects of essential care may be compromised
if initial HSCT treatment is delivered outside of their home
country, especially if communication between clinicians is
limited. It is, therefore, important that patients specifically
address these issues prior to HSCT treatment as they may
require ongoing engagement with clinical services near their
home (in both planned or unplanned settings, i.e., emergency
or urgent care).
Following return to home, some health services may not
support monitoring and follow-up following HSCT,
and this may lead to further financial commitment from
the patient. The EBMT therefore recommend that before
proceeding to transplants, patients carefully assess
arrangements and support for medium- and long-term
monitoring and follow-up in their locally available health
services.
Summary
● Haematopoietic stem cell transplantation (HSCT) has
been used in patients with severe autoimmune and
inflammatory diseases whose response to standard
treatment options has been limited and associated with
a poor long-term prognosis in terms of survival and/or
disability. The vast majority of patients have received
autologous HSCT, with the use of allogeneic HSCT
being rare and mainly in paediatric patients.
● Although a wide range of autoimmune diseases have
been treated, the evidence base is greatest for the use of
autologous HSCT in relapsing remitting MS, diffuse
systemic sclerosis and Crohn’s disease.
● HSCT may work by ‘re-setting‘ or ‘re-booting’ the
immune system, which in turn may lead to improvement
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Centre activity for AD overall, 2012-2017 (≥10 autologous HSCT procedures)
Centre activity, MS and other neurological AD, 2012-2017 (≥5 autologous HSCT procedures)





















































































































































Centre activity for AD overall, 2012-2017 (≥10 autologous HSCT procedures)
Centre activity, MS and other neurological AD, 2012-2017 (≥5 autologous HSCT procedures)
Centre activity for rheumatological AD, 2012-2017 (≥3 autologous HSCT procedures)
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in damaged organs and tissues. HSCT works best if
active inflammation can be switched off, but the
effect of HSCT may be limited (or no benefit at all) if
there is no active inflammation. There is no proof that
the blood stem cells can directly rebuild specialised
tissues, although the absence of inflammation may
enable some damaged tissues and organs to heal over
time.
● Compared with most standard treatments, HSCT is
associated with greater short-term risks, including a risk
of treatment related mortality (TRM), and long-term
complications (so called ‘late effects’) due to the
intensity of the treatment. The risk of complications is
higher with autologous HSCT in some types of diseases
and in allogeneic HSCT. Risks increase with age, more
advanced disease and the presence of other conditions
which affect patients’ fitness. Decisions should be
individualised for each patient.
● Before decisions to proceed with HSCT can be made, it
is essential to carry out a careful joint appraisal of
potential benefits and risks by disease and transplant
specialists working closely together with patients and
carers. Alternative non-transplant treatments should
always be a consideration in decision-making.
● The EBMT and other professional societies have
summarised the evidence and produced guidelines and
recommendations as a resource to support centres and
good clinical practice.
● HSCT should be conducted in accredited units with
robust arrangements for early referral for urgent care
after the transplant and long-term follow up with both
disease and transplant specialists. Centres should
routinely submit data on transplanted patients to
international registries, such as EBMT.
● Treatment and follow-up on a clinical trial should
always be considered, if available within a reasonable
geographical reach of the patient’s home.
● Patients considering HSCT treatment abroad for their
AD are strongly advised to ensure that expectations in
this position statement are met by the centre offering
treatment and that robust referral and follow-up
arrangements are made with their local disease and
transplant specialists. Independent self-referral is strongly
discouraged.






































Centre activity for gastrointestinal AD, 2012-2017 (≥2 autologous HSCT procedures)
Centre activity for gastrointestinal AD, 2012-2017 (≥2 autologous HSCT procedures)
Fig. 3 a–d Activity and JACIE accreditation status in EBMT reporting
centres for autologous HSCT in autoimmune diseases. a Overall. bMS
and neurological diseases. c Systemic sclerosis and rheumatological
diseases. d Crohn’s disease and gastrointestinal diseases. Activity is
for autologous procedures from 2012–2017 inclusive, i.e., reflecting
practice after the publication of EBMT ADWP Guidelines [12].
Accreditation status is indicated by asterisks as active and/or with re-
accreditation in progress as per December 2018 (www.JACIE.org).
Centre identities according to CIC code are available on https://www.
ebmt.org/ebmt-membership-list. The information is primarily intended
as a resource for clinicians in transplant centres and disease specialists
who wish to make contact with experienced EBMT centres for advice,
support, referral or other partnership arrangements aimed at optimising
patient care whilst accommodating geographical considerations. The
information may also be useful to patients and other carers; however,
independent self-referral is strongly discouraged. MS multiple sclero-
sis, SSc systemic sclerosis, CD Crohn’s disease, MGmyasthenia
gravis, CIDP chronic inflammatory demyelinating polyneuropathy,
NMO neuromyelitis optica
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The EBMT ADWP is dedicated to promoting clinical
activities, teaching and performing translational research.
Our focus is mainly on autologous/allogeneic HSCT,
together with of novel forms of cellular therapy and new
immunosuppressive drugs in a specific challenge to induce
tolerance, with the ultimate objective of better under-
standing the possibility of resetting the immune response
during treatment of severe autoimmune diseases. The
EBMT ADWP also has the strategic task of interacting with
other autoimmune diseases (AD) specialists and their
respective scientific societies.
The EBMT Nurses Group
https://www.ebmt.org/nurses-group
The EBMT Nurses Group (NG) plays an essential role in
haematology and haematological stem cell transplantation
nursing. The group was created 33 years ago and now has
over 750 members in more than 60 countries worldwide
with a principal nurse identified in almost each EBMT
centre. The EBMT NG’s mission is to enhance and value
the nurses’ role all over the world, supporting and sharing
knowledge through communication, advocacy, research,
training and education. The group is dedicated to improving
the care of patients receiving stem cell transplantation and
works towards promoting excellence in care through
recognizing, building upon and providing evidence-based
practice.
The EBMT patient, family and donor committee
https://www.ebmt.org/patient-family-and-donor-
committee
The objectives of the EBMT patient, family and donor
committee include supporting national patient advocacy
groups, providing a pan-European platform for patient
advocacy groups including a patient dedicated link on
EBMT website and providing advice on how to optimise
EBMT patient centred activities. In addition, the committee
aims to increase the numbers of international patients,
family members and donors to access the EBMT patient,
family and donor day at the annual meeting by promoting
the use of online webcasts and translation.




JACIE develops and maintain global standards for the
provision of quality medical and laboratory practice in
cellular therapy. Based on these standards, JACIE offers
accreditation to transplant programmes in order to encou-
rage health institutions and facilities to establish and
maintain quality management systems impacting on all
aspects of their activities and to engage in continuous
improvement. JACIE's primary aim is to promote high-
quality patient care and laboratory performance in collec-
tion, processing and transplantation centres through an
internationally recognised system of accreditation.
Paris EBMT Office
More technical information for clinicians, including
contact with key centres, is available from the Paris EBMT
Office via Manuela Badoglio, ADWP Study Coordinator,
manuela.badoglio@upmc.fr who has access to haematolo-
gists and disease specialists working in your region and
countries via the EBMT registry and can liaise with mem-
bers of the EBMT.
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